Riyadh: The Local Content and Government Procurement Authority (LCGPA) announced the signing of five agreements to localize the manufacturing and knowledge transfer of several medical and pharmaceutical products.
According to Saudi Press Agency, the agreements were finalized on the sidelines of the Global Health Exhibition 2025, in the presence of Minister of Industry and Mineral Resources and Chairman of LCGPA's Board of Directors Bandar Alkhorayef, and CEO of LCGPA Abdulrahman Al-Samari. These agreements are part of the authority's ongoing efforts to enhance local content in strategic sectors and empower national industries in the healthcare and pharmaceutical fields.
The ceremony concluded with the signing of a localization agreement for etanercept, a biologic drug used to reduce inflammation and treat chronic inflammatory diseases, encompassing both its manufacture and knowledge transfer. Among these initiatives is the localization of orthopedic implants for treating accidents and fractures, including devices designed to address bone fractures and deformities.
Additionally, the authority signed a localization agreement for adalimumab, a biologic drug used to treat a variety of chronic inflammatory diseases caused by an overactive immune system. The agreement was signed separately with Boston Oncology and Tabuk Pharmaceuticals.